|
|
Substance Name: Haloperidol [USAN:USP:INN:BAN:JAN]
RN: 52-86-8
UNII: J6292F8L3D
InChIKey: LNEPOXFFQSENCJ-UHFFFAOYSA-N
Note
- A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279).
Molecular Formula
- C21-H23-Cl-F-N-O2
Molecular Weight
- 375.8687
- All
- Classifications
- Links to Resources
- Names & Synonyms
- Registry Numbers
- Structure Descriptors
- Toxicity
- Physical Properties
Classification Codes
- Anti-Dyskinesia Agents
- Antidyskinetic (in Gilles De La Tourette's Disease)
- Antiemetics
- Antipsychotic
- Antipsychotic Agents
- Autonomic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Dopamine Agents
- Dopamine Antagonists
- Drug / Therapeutic Agent
- Gastrointestinal Agents
- Human Data
- Mutation Data
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Psychotropic Drugs
- Reproductive Effect
- Tranquilizing Agents
- Tumor Data
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Regulatory Agencies (Superlist Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Haloperidol
- Haloperidol [USAN:USP:INN:BAN:JAN]
MeSH Heading
- Haloperidol
Synonyms
- 1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
- 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-
- 4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
- 4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
- 4'-Fluoro-4-(4-hydroxy-4-p-chlorophenylpiperidino)butyrophenone
- 4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone
- 4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
- 4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone
- 5-21-02-00377 (Beilstein Handbook Reference)
- Aldo
- Aloperidin
- Aloperidol
- Aloperidolo
- Aloperidolo [DCIT]
- Aloperidolo [Italian]
- BRN 0331267
- Brotopon
- Butyrophenone, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-
- Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-
- CCRIS 1630
- Dozic
- Einalon S
- EINECS 200-155-6
- Eukystol
- Fortunan
- Galoperidol
- gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone
- gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorobutyrophenone
- Haldol
- Haldol Solutab
- Halojust
- Halopal
- Haloperidol
- Haloperidolum
- Haloperidolum [INN-Latin]
- Halopoidol
- HSDB 3093
- Keselan
- Lealgin compositum
- Linton
- McN-JR-1625
- Mixidol
- NSC 170973
- NSC 615296
- Peluces
- Pernox
- R 1625
- R-1625
- Serenace
- Serenase
- Serenelfi
- Sernas
- Sernel
- Ulcolind
- Uliolind
- UNII-J6292F8L3D
- Vesalium
Systematic Names
- 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-
- Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-
- Haloperidol
Superlist Name
- Haloperidol
Registry Numbers
CAS Registry Number
- 52-86-8
FDA UNII
- J6292F8L3D
System Generated Number
- 0000052868
Structure Descriptors
InChI
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2InChIKey
LNEPOXFFQSENCJ-UHFFFAOYSA-NSmiles
OC1(CCN(CCCC(=O)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
cat | LD50 | subcutaneous | > 2500ug/kg (2.5mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961. | |
child | TDLo | oral | 72ug/kg (0.072mg/kg) | BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | American Journal of Psychiatry. Vol. 143, Pg. 1176, 1985. |
child | TDLo | unreported | 375ug/kg/3D (0.375mg/kg) | BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Lancet. Vol. 2, Pg. 479, 1980. |
dog | LD50 | intravenous | 18mg/kg (18mg/kg) | Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967. | |
dog | LD50 | oral | 90mg/kg (90mg/kg) | Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967. | |
dog | LD50 | subcutaneous | > 80mg/kg (80mg/kg) | Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967. | |
human | TDLo | oral | 71ug/kg (0.071mg/kg) | BEHAVIORAL: EXCITEMENT | Journal of Clinical Pyschopharmacology. Vol. 5, Pg. 120, 1985. |
human | TDLo | unreported | 9800ug/kg/28D (9.8mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA | Arzneimittel-Forschung. Drug Research. Vol. 32, Pg. 911, 1982. |
infant | TDLo | unreported | 280ug/kg (0.28mg/kg) | BEHAVIORAL: IRRITABILITY BEHAVIORAL: EXCITEMENT BEHAVIORAL: AGGRESSION | Acta Paediatrica. Vol. 82, Pg. 877, 1993. |
mammal (species unspecified) | LD50 | oral | 80mg/kg (80mg/kg) | Doklady Akademii Nauk SSSR. Proceedings of the Academy of Sciences of the USSR. For English translation, see DBIOAM and DKBSAS. Vol. 320, Pg. 242, 1991. | |
mammal (species unspecified) | LD50 | unreported | 80mg/kg (80mg/kg) | Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(7), Pg. 27, 1990. | |
man | TDLo | multiple routes | 343ug/kg (0.343mg/kg) | BEHAVIORAL: TREMOR | Southern Medical Journal. Vol. 76, Pg. 546, 1983. |
man | TDLo | multiple routes | 1mg/kg/1D-I (1mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS | Journal of Clinical Pyschopharmacology. Vol. 3, Pg. 338, 1983. |
man | TDLo | oral | 480ug/kg/6D-I (0.48mg/kg) | BEHAVIORAL: REGIDITY BEHAVIORAL: EXCITEMENT BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | American Journal of Psychiatry. Vol. 142, Pg. 389, 1985. |
man | TDLo | oral | 9mg/kg/30W-I (9mg/kg) | PERIPHERAL NERVE AND SENSATION: FASCICULATIONS | Biological Psychiatry. Vol. 22, Pg. 111, 1987. |
man | TDLo | unreported | 500ug/kg/5D-I (0.5mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | JAMA, Journal of the American Medical Association. Vol. 250, Pg. 485, 1983. |
monkey | LD50 | subcutaneous | > 1250ug/kg (1.25mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961. | |
mouse | LD50 | intraperitoneal | 30mg/kg (30mg/kg) | Bollettino Chimico Farmaceutico. Vol. 111, Pg. 293, 1972. | |
mouse | LD50 | intravenous | 13mg/kg (13mg/kg) | BEHAVIORAL: ATAXIA BEHAVIORAL: REGIDITY | Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961. |
mouse | LD50 | oral | 71mg/kg (71mg/kg) | Farmaco, Edizione Scientifica. Vol. 31, Pg. 442, 1976. | |
mouse | LD50 | subcutaneous | 41mg/kg (41mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 1, Pg. 74, 1967. | |
mouse | LD50 | unreported | 18mg/kg (18mg/kg) | Clinical Pharmacology and Therapeutics Vol. 3, Pg. 432, 1962. | |
rabbit | LD50 | intravenous | 8mg/kg (8mg/kg) | Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967. | |
rat | LD50 | intraperitoneal | 27mg/kg (27mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 190, 1972. | |
rat | LD50 | intravenous | 15mg/kg (15mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 45, 1974. | |
rat | LD50 | oral | 128mg/kg (128mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 45, 1974. | |
rat | LD50 | subcutaneous | 60mg/kg (60mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 45, 1974. | |
women | TDLo | intravenous | 18300ug/kg/7D (18.3mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Annals of Pharmacotherpy. Vol. 33, Pg. 1046, 1999. |
women | TDLo | oral | 100ug/kg/10D- (0.1mg/kg) | BLOOD: AGRANULOCYTOSIS | Journal of the American Geriatrics Society. Vol. 35, Pg. 248, 1987. |
Physical Properties
Physical Property | Value | Units | Temp (deg C) | Source |
---|---|---|---|---|
Melting Point | 151.5 | deg C | EXP | |
pKa Dissociation Constant | 8.66 | (none) | EXP | |
log P (octanol-water) | 4.3 | (none) | EXP | |
Water Solubility | 14 | mg/L | 25 | EXP |
Vapor Pressure | 4.85E-11 | mm Hg | 25 | EST |
Henry's Law Constant | 2.26E-14 | atm-m3/mole | 25 | EST |
Atmospheric OH Rate Constant | 1.16E-10 | cm3/molecule-sec | 25 | EST |
Physical property data is provided to ChemIDplus by SRC, Inc.